Publications by authors named "Daniel Nava Rodrigues"

50Publications

Genetic Analysis of Circulating Tumour Cells.

Recent Results Cancer Res 2020 ;215:57-76

The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article and Find Full Text PDF
October 2019

Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp.

Eur J Cancer 2019 11 7;122:9-11. Epub 2019 Oct 7.

Drug Development Unit, The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, London, SM2 5PT, United Kingdom. Electronic address:

View Article and Find Full Text PDF
November 2019

The molecular underpinnings of prostate cancer: impacts on management and pathology practice.

J Pathol 2017 Jan 1;241(2):173-182. Epub 2016 Dec 1.

The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.

View Article and Find Full Text PDF
January 2017

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

Clin Genitourin Cancer 2016 12 5;14(6):485-493. Epub 2016 May 5.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article and Find Full Text PDF
December 2016

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

Cancer Res 2016 05;76(9):2731-42

Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom. Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.

View Article and Find Full Text PDF
May 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med 2015 Oct;373(18):1697-708

From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.).

View Article and Find Full Text PDF
October 2015

Molecular pathology and prostate cancer therapeutics: from biology to bedside.

J Pathol 2014 Jan;232(2):178-84

Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK.

View Article and Find Full Text PDF
January 2014